Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation

Drug Safety

Volumn 36, Issue 2, 2013, Pages 93-110

  Adlan, Ahmed M A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; CREATININE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DABIGATRAN; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; DRUG METABOLITE; FLECAINIDE; MACROLIDE; PLACEBO; PROCAINAMIDE; PROPAFENONE; PROTEINASE INHIBITOR; QUINIDINE; SIMVASTATIN; SOTALOL;

ABDOMINAL PAIN; ACUTE LIVER FAILURE; ANGINA PECTORIS; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLURRED VISION; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIGOXIN BLOOD LEVEL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EXTRASYSTOLE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFECTION; INSOMNIA; INTERSTITIAL LUNG DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG FIBROSIS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT MONITORING; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PLASMA CONCENTRATION-TIME CURVE; PR INTERVAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SINUS RHYTHM; STEADY STATE; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; THYROID DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT DURATION; VISUAL DISORDER; VOMITING;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEART RATE; HUMANS; RISK ASSESSMENT;

EID: 84876543830     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-012-0012-8     Document Type: Review

References (68)

1. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost. 2011;9(1):344-51.
2. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6:981-93.
3. Ruder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1999;84(9A):131-8R.
4. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57(2):223-42.
5. Camm J, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
6. National Institute for Health and Clinical Excellence. CG36, atrial fibrillation (CG36). The management of atrial fibrillation. 2006. http://www.nice.org.uk/CG036. Accessed 20 Dec 2011.
7. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-8.
8. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40.
9. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-6.
10. Opolski G, Torbicki A, Kosior D, et al. Rate control v rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) study. Chest. 2004;126(2):476-86.
11. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77.
12. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet. 2000;356(9244):1789-94.
13. Mazzini MJ, Monahan KM. Pharmacotherapy for atrial arrhythmias: present and future. Heart Rhythm. 2008;5(6 Suppl):S26-31.
14. Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 2011;18(6):138-45S.
15. Han TS, Williams GR, Vanderpump MPJ. Benzfuran derivatives and the thyroid. Clin Endocrinol (Oxf). 2009;70(1):2-13.
16. US FDA. FDA news release. FDA approves Multaq to treat heart rhythm disorder. 2 Jul 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm170276.htm. Accessed 21 Dec 2011.
17. European Medicines Agency. European Public Assessment Report for Multaq. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/001043/WC500044536.pdf. Accessed 21 Dec 2011.
18. US FDA. Multaq prescribing information 2012. http://www.accessdata.fda. gov/drugsatfda-docs/label/2012/022425s002lbl.pdf. Accessed 20 Apr 2012.
19. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-76.
20. European Medicines Agency. Multaq summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001043/WC500044534.pdf. Accessed 20 Apr 2012.
21. Le Heuzey J-Y, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597-605.
22. Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 2005;23(3):217-30.
23. Agelaki MG, Pantos C, Korantzopoulos P, et al. Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. Eur J Pharmacol. 2007;564(1-3):150-7.
24. Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular tachycardia. Vasc Health Risk Manag. 2010;6:465-72.
25. Oyetayo OO, Rogers CE, Hofman PO. Dronedarone: a new antiarrhythmic agent. Pharmacotherapy. 2010;30(9):904-15.
26. Wolbretter D, Gonzalez M, Samii S, et al. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. Vasc Health Risk Manag. 2010;6:517-23.
27. Baroletti S, Catella J, Ehle M, et al. Dronedarone: a review of characteristics and clinical data. Crit Pathw Cardiol. 2010;9(2):94-101.
28. Lalevee N, Nargeot J, Barrere-Lemaire S, et al. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003;14:885-90.
29. Guillemare E, Marion A, Nisato D, et al. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000;36:802-5.
30. Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003;41:191-202.
31. Gautier P, Marion A, Bertrand JP, et al. Electrophysiological characterization of dronedarone (SR33589), a new amiodarone-like agent, in cardiac ventricular myocytes. Eur Heart J. 1997;18(Suppl):269.
32. Rochetti M, Bertrand JP, Nisato D, et al. Cellular electrophysiological study of dronedarone, a new amiodarone-like agent, in guinea pig sinoatrial node. Nauyn Schmiedebergs Arch Pharmacol. 1998;358(1 Suppl 2):R617.
33. Aimond F, Beck L, Gautier P, et al. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J Pharmacol Exp Ther. 2000;292:415-24.
34. Chatelain P, Meysmans L, Matteazzi JR, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995;116:1949-56.
35. Djandjighian L, Planchenault J, Finance O, et al. Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction. J Cardiovasc Pharmacol. 2000;36:376-83.
36. Hodeige D, Heyndrickx JP, Chatelain P, et al. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995;279:25-32.
37. Sun W, Sharma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart comparison with amiodarone. Circulation. 1999;100:2276-81.
38. Sun W, Sharma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002;39(5):677-84.
39. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104:2722-7.
40. Manning AS, Bruyninckx C, Ramboux J, et al. SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol. 1995;26(3):453-61.
41. Rochetaing A, Barbe C, Kreher P. Beneficial effects of amiodarone and dronedarone (SR 33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters assessed during reperfusion in isolated rat hearts. J Cardiovasc Pharmacol. 2001;38(4):500-11.
42. Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, d,l-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol. 1995;26(4):570-6.
43. Verduyn SC, Vos MA, Leunissen HD, et al. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsades de pointes arrhythmias. J Cardiovasc Pharmacol. 1999;33:212-22.
44. Mitchell LB, Wyse DG, Gillis AM, et al. Electropharmacology of amiodarone therapy initiation: time course of onset of electrophysiologic and antiarrhythmic effects. Circulation. 1989;80:34-42.
45. ®. Date of revision September 12, 2012. http://products.sanofi.ca/en/multaq.pdf. Accessed 20 Apr 2012.
46. Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther. 2010;15(4):15-8S.
47. Patel C, Yan G-X, Kowey PR. Dronedarone. Circulation. 2009;120(7):636-44.
48. Anastasiou-Nana M, Levis GM, Moulopoulos S. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol. 1982;20(11):524-9.
49. Andreasen F, Agerbaek H, Bjerregaard P, et al. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol. 1981;19(4):293-9.
50. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64(6):785-91.
51. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987-99.
52. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970;39(4):657-67.
53. Counihan PJ, McKenna WJ. Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias. Drug Saf. 1990;5(4):286-304.
54. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J. 1983;106(4):840-7.
55. Pourbaix S, Berger Y, Desager JP, et al. Absolute bioavailability of amiodarone in normal subjects. Clin Pharmacol Ther. 1985;37(2):118-23.
56. Plomp TA, van Rossum JM, Robles de Medina EO, et al. Pharmacokinetics and body distribution of amiodarone in man. Arzneimittelforschung. 1984;34(4):513-20.
57. Adams PC, Holt DW, Storey GC, et al. Amiodarone and its desethyl metabolite: tissue distribution and morphologic during long-term therapy. Circulation. 1985;72(5):1064-75.
58. Meng Z, Mojaverian P, Doedee M, et al. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol. 2001;87(4):432-5.
59. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(16):1481-7.
60. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156(3):527e1-9.
61. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668-78.
62. Duray GZ, Torp-Pedersen C, Connolly SJ, et al. Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. J Cardiovasc Electrophysiol. 2011;22(7):770-6.
63. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678- 87.
64. US FDA. Drug safety communication: severe liver injury associated with the use of dronedarone (marketed as Multaq). http://www.fda.gov/drugs/ drugsafety/ucm240011.htm. Accessed 21 Dec 2011.
65. Vallakati A, Chandra PA, Pednekar M, et al. Dronedarone-induced digoxin toxicity: new drug, new interactions. Epub: Am J Ther; 2011.
66. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-8.
67. US FDA. Drug safety communication: review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. http://www.fda.gov/Drugs/DrugSafety/ucm283933. Accessed 21 Dec 2011.
68. Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54:1089-95.